Last reviewed · How we verify
Prandin (repaglinide)
Repaglinide lowers blood glucose levels by stimulating insulin release from the pancreas through ATP-dependent potassium channel blockade.
At a glance
| Generic name | repaglinide |
|---|---|
| Sponsor | Novo Nordisk |
| Drug class | Glinide [EPC] |
| Target | ATP-binding cassette sub-family C member 8 |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1997 |
Mechanism of action
Repaglinide works by binding to characterizable sites on ATP-dependent potassium channels in the beta cell membrane. This binding causes the potassium channels to close, leading to depolarization of the beta cell. The depolarization opens calcium channels, allowing an influx of calcium ions into the cell. The increased calcium levels trigger the release of insulin from the beta cell. This action is glucose-dependent, meaning that insulin release is only stimulated when glucose levels are high. At low glucose concentrations, insulin release is diminished.
Approved indications
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- Not for treatment of type 1 diabetes mellitus
- Not for treatment of diabetic ketoacidosis
Common side effects
- Hypoglycemia
- Upper Respiratory Infection
- Headache
- Sinusitis
- Arthralgia
- Nausea
- Diarrhea
- Back Pain
- Rhinitis
- Constipation
- Vomiting
- Paresthesia
Drug interactions
- ciprofloxacin
- levofloxacin
- norfloxacin
- ofloxacin
- rifabutin
- rifampicin
- rifapentine
Key clinical trials
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (PHASE1)
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants (PHASE1)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (PHASE1, PHASE2)
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (PHASE1)
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prandin CI brief — competitive landscape report
- Prandin updates RSS · CI watch RSS
- Novo Nordisk portfolio CI